Keros Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Thanks for joining us here at Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro from Piper's biotech team. It's my pleasure to welcome Keros Therapeutics and their CEO, Jas Seehra. Jas, thanks so much for joining us. Obviously, probably a lot to get through in 25 minutes. I could probably ask you like one question on activin A, and that clock will beat the zero.
But maybe to just start things off -- because there are a lot of things to get through -- could just sort of help level set the discussion, introduced Keros, what you guys are about? And then we'll jump into, I think, each specific program and data set that's expected at ASH.
Yeah, I think to put it simply, Keros is focused on the TGF-beta pathway to develop therapeutics that are differentiated. And you see that in our pipeline, with 050 increasing red blood cells as well as platelets. Therefore, it's going after MDS, myelofibrosis. 047 deals with a different aspect that's there in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
